Armata Pharmaceuticals (id:219 ARMP)
2.10 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/22/2024 8:09:44 AM)
Exchange closed, opens in 1 hour 20 minutes
About Armata Pharmaceuticals
Market Capitalization 81.05M
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
| Headquarters (address) |
5005 McConnell Avenue Los Angeles 90066 CA United States |
| Phone | 310 665 2928 |
| Website | https://www.armatapharma.com |
| Employees | 66 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ARMP |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 1.98 - 4.48 |
| Market Capitalization | 81.05M |
| P/E trailing | -1.10 |
| P/E forward | -1.43 |
| Price/Sale | 21.79 |
| Price/Book | -1.49 |
| Beta | 0.805 |
| EPS | -1.86 |
| EPS United States (ID:6, base:3395) | 24.30 |